This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Back to Drug Candidates

Everolimus

Afinitor

mTOR inhibitor (rapalog)

Evidence Score

55

preclinical
Mechanism of Action

Binds FKBP12 to form a complex that inhibits mTORC1, blocking downstream signaling including S6K1 and 4E-BP1. Reduces cell growth, proliferation, and angiogenesis. Rationale in SDH-deficient tumors comes from metabolic reprogramming-driven mTOR activation.

Pathway Connections
mTOR / PI3K / AKT

Metabolic reprogramming from SDH loss activates the PI3K/AKT/mTOR signaling axis, promoting cell growth, proliferation, and survival. Multiple upstream inputs converge on mTOR.

Upstream event:

HIF-mediated growth factor signaling + metabolic stress + AMPK dysregulation

Downstream effects:

Cell growth and proliferationProtein synthesisMetabolic reprogrammingSurvival signaling
Molecular Targets

MTOR

Mechanistic target of rapamycin

downstream

Central growth/metabolism regulator activated downstream of SDH loss. Target of everolimus and temsirolimus.

UniProt: P42345

Quick Facts
FDA Approved

Approved Indications

  • Advanced renal cell carcinoma
  • Pancreatic neuroendocrine tumors
  • Breast cancer (HR+/HER2-)
  • Tuberous sclerosis complex
ChEMBL IDCHEMBL1237021
PubChem CID6442177
Evidence

Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.

Coming in Phase 3

For research exploration only — not medical advice. Consult your doctor before acting on any information.

AI Analysis

Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.